For instance, clinical infusion of EGFRvIII-directed CAR-T cells for the treatment of glioblastoma resulted in influx of CD4+CD25+FoxP3+ cells in the tumor (38), whereas CD19-targeted CAR-T cells against B-cell lymphoma and leukemia did not increase the frequency of Treg cells (57). The gene discussed is IL2RA; the disease is neoplasm.